Frontotemporal dementia (FTD) is a common neurodegenerative disorder and an early-onset form of dementia, characterized by prominent psychiatric and behavioral abnormalities and cognitive impairment. Due to its unclear pathogenesis and marked heterogeneity, early diagnosis and treatment are currently challenging. In recent years, as technology has matured, research on FTD biofluid markers has become a hot topic, with many studies identifying potential marker molecules for application. This article summarizes recent related research in order to provide clinicians with an understanding of the progress in early diagnostic markers for FTD, to offer reference directions for subsequent basic research, and to present possible options for clinical application.